Addressing Disparities in the Quality of Breast Cancer Chemotherapy

Published in: Clinical Breast Cancer, v. 6, no. 3, Commentary, Aug. 2005, p. 267-269

Posted on on January 01, 2005

by Jennifer J. Griggs, Melony E. Sorbero

Read More

Access further information on this document at

This article was published outside of RAND. The full text of the article can be found at the link above.

Commentary on a study in this issue that examines disparities in the quality of breast cancer adjuvant chemotherapy received by black and white women within a university setting, and found that black women are more likely than white women to have delays in administration of chemotherapy, reductions in doses, and premature discontinuation of therapy.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.